Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 5/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CD38 | P28907 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714582 | 0.89 | CNR2 (0.37) | OPRL1KLKB1MCHR1CD38 | |
| SCHEMBL30714749 | 0.89 | OPRL1 (0.35) | OPRL1KLKB1GCKMCHR1POLB | |
| SCHEMBL30714598 | 0.86 | OPRL1 (0.35) | OPRL1KLKB1GCKMCHR1CD38 | |
| SCHEMBL30714732 | 0.86 | ALDH1A1 (0.43) | POLBMAPT | |
| SCHEMBL30714583 | 0.85 | OPRL1 (0.33) | OPRL1KLKB1GCKMCHR1CD38 | |
| SCHEMBL26868368 | 0.85 | OPRL1 (0.34) | OPRL1KLKB1MCHR1CD38GRM2 | |
| SCHEMBL26696066 | 0.85 | OPRL1 (0.33) | OPRL1KLKB1GCKMCHR1CD38 | |
| SCHEMBL30714680 | 0.84 | SCN9A (0.38) | OPRL1CACNA1GCACNA1HCACNA1IGRM2 | |
| SCHEMBL30714557 | 0.84 | NPC1 (0.37) | OPRL1KLKB1MCHR1POLBMAPT | |
| SCHEMBL26696085 | 0.84 | NPC1 (0.37) | OPRL1KLKB1MCHR1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| CN-119968362-A | Indazole derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-05-09 | — | — | CN | disclosed |
| EP-4499624-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | TYK2 3610/4885OPRL1 112/4885KLKB1 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.